TENX: Guggenheim Raises PT
Guggenheim maintains buy rating on Tenax Therapeutics and raises price target to $40
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Guggenheim maintains buy rating on Tenax Therapeutics and raises price target to $40
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.